ClinicalTrials.gg
CompletedNCT01998893Updated Dec 3, 2014Results posted

A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

A Phase 2 interventional study of rituximab [MabThera/Rituxan] in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 11 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-03.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
86th of 171
38 · median 38
Started
1997
with 3 others
Phase 2
94 of 178
3 open now
Registered
141st of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 86th largest by enrollment of the 171 interventional ones that give a count, is one of 4 that started in 1997, is one of 94 in phase 2, and was the 141st registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma. Patients will receive once-weekly intravenous MabThera/Rituxan for 4 weeks; responding patients will be treated a second time in case of relapse (defined as progression after complete or partial response). The anticipated time on study treatment is \<3 months.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients >= 18 years of age;
  • centrocytic centroblastic non-Hodgkin's lymphoma stage III-IV;
  • relapse after chemotherapy (with or without interferon maintenance therapy).

Exclusion criteria

Exclusion Criteria:

  • primary lymphomas;
  • more than 3 relapses of centroblastic centrocytic non-Hodgkin's lymphoma;
  • cardiac disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    MabThera/Rituxan

    Drug: rituximab [MabThera/Rituxan]

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR)

    Percentage of participants with a CR, PR at the end of the first cycle of treatment (Week 4). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1.500/ microliter (µL), hemoglobin (Hb) \>12 grams per deciliter (g/dL), and platelets \>100,000/µL. PR was defined as a less than (\<) 50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts.

    Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)

Secondary outcomes

  1. Number of Participants With a Clinical Response

    Clinical response was defined as the best response after the first 4 weeks of treatment cycle by the following categories: CR, PR, minor response (MR), stable disease (SD), and progressive disease (PD). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.

    Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)

  2. Time to Best Response

    The median time, in months, from start of the treatment (first application) until best response (PR or CR).

    Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)

  3. Duration of Remission

    Median time, in months, between the documentation of CR or PR and PD in clinical responders.

    Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)

  4. Time to Progression

    The median time, in months, from the start of treatment (first application) until detection of PD.

    Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)

  5. Overall Survival (OS)

    OS was defined as the time, in months, between enrollment into the study and death, due to any cause. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.

    Time frame: Enrollment into study until end of follow-up or death. The median length of follow-up was 6.6 months (range: 0-97.8 months)

  6. Number of Participants With a Clinical Response to Re-Treatment

    Clinical response was defined as the best response after the second 4 weeks of treatment cycle by the following categories: CR, PR, MR, SD, and PD. CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.

    Time frame: First application in the second treatment cycle until progression of disease. The median length of follow-up was 4.6 months (range: 0.5-20.6 months).

07

Results

Posted Nov 4, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab
Started38
1st treatment cycle completed until pd30
2nd treatment cycle started5
2nd treatment cycle completed until pd3
Completed21
Not completed17
Withdrew: Adverse event2
Withdrew: Death1
Withdrew: Lost to follow-up8
Withdrew: Physician decision2
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject1
Withdrew: Transformation to high-grade lymphoma1

Outcome measures

PrimaryPercentage of Participants With a Complete Remission (CR) or Partial Remission (PR)

Percentage of participants with a CR, PR at the end of the first cycle of treatment (Week 4). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1.500/ microliter (µL), hemoglobin (Hb) \>12 grams per deciliter (g/dL), and platelets \>100,000/µL. PR was defined as a less than (\<) 50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts.

Time frame:
Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR)
percentage of participantsRituximab
Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR)39.5 (24.0 to 56.6)
SecondaryNumber of Participants With a Clinical Response

Clinical response was defined as the best response after the first 4 weeks of treatment cycle by the following categories: CR, PR, minor response (MR), stable disease (SD), and progressive disease (PD). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.

Time frame:
Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Reported as:
Number · participants
Number of Participants With a Clinical Response
participantsRituximab
CR9
PR6
MR3
SD16
PD2
Missing2
SecondaryTime to Best Response

The median time, in months, from start of the treatment (first application) until best response (PR or CR).

Time frame:
Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Reported as:
Median · months
Time to Best Response
monthsRituximab
Time to Best Response1.9 (1.1 to 5.7)
SecondaryDuration of Remission

Median time, in months, between the documentation of CR or PR and PD in clinical responders.

Time frame:
Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Reported as:
Median · months
Duration of Remission
monthsRituximab
Duration of Remission12.7 (5.6 to 35.0)
SecondaryTime to Progression

The median time, in months, from the start of treatment (first application) until detection of PD.

Time frame:
Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Reported as:
Median · months
Time to Progression
monthsRituximab
Time to Progression6.6 (4.8 to 15.3)
SecondaryOverall Survival (OS)

OS was defined as the time, in months, between enrollment into the study and death, due to any cause. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.

Time frame:
Enrollment into study until end of follow-up or death. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Reported as:
Median · months
Overall Survival (OS)
monthsRituximab
Overall Survival (OS)49.6 (15.3 to NA)
SecondaryNumber of Participants With a Clinical Response to Re-Treatment

Clinical response was defined as the best response after the second 4 weeks of treatment cycle by the following categories: CR, PR, MR, SD, and PD. CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.

Time frame:
First application in the second treatment cycle until progression of disease. The median length of follow-up was 4.6 months (range: 0.5-20.6 months).
Reported as:
Number · participants
Number of Participants With a Clinical Response to Re-Treatment
participantsRituximab
CR1
PR0
MR0
SD3
PD0
Missing1

Adverse events

Collected over Adverse events (AEs) were reported from the beginning of study treatment until PD or last available follow-up in the first or the second treatment cycle. The median length of follow up was 6.7 months (range: 0-97.8 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—10/38 (26.3%)34/38 (89.5%)
Most frequent serious events
Most frequent serious events
EventRituximab
LymphocytesBlood and lymphatic system disorders2/38
Sinus tachycardiaCardiac disorders2/38
AllergyImmune system disorders1/38
DysrhythmiasCardiac disorders1/38
Lethargy (fatigue, malaise)General disorders1/38
InfectionInfections and infestations1/38
HypoglycemiaMetabolism and nutrition disorders1/38
Shortness of breath (including wheezing)Respiratory, thoracic and mediastinal disorders1/38
Most frequent other events
Showing 10 of 36
Most frequent other events
EventRituximab
Fever in absence of infection (including drug fever)General disorders14/38
Rigor/chills (grade 3 including cyanosis)General disorders12/38
InfectionInfections and infestations12/38
HeadacheNervous system disorders7/38
Rash/itch (not due to allergy, including recall reaction)Skin and subcutaneous tissue disorders7/38
PlateletsBlood and lymphatic system disorders6/38
Metabolic: other (not specified)Metabolism and nutrition disorders6/38
LymphocytesBlood and lymphatic system disorders5/38
NauseaGastrointestinal disorders5/38
Lethargy (fatigue, malaise)General disorders5/38

Baseline characteristics

Intent to treat (ITT) population included all participants with at least 1 application of study treatment.

Age, Continuous
Age, Continuous(years)Rituximab
Median55 (26 to 75)
Age, Customized
Age, Customized(participants)Rituximab
Less Than or Equal to (≤) 18 Years0
Between 18 and 65 Years32
Greater Than or Equal to (≥) 65 Years6
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female25
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rituximab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White38
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Rituximab
Germany38
Ann Arbor stage
Ann Arbor stage(participants)Rituximab
Stage III5
Stage IV33
Histological subtype
Histological subtype(participants)Rituximab
Follicular or centroblastic/centrocytic lymphoma32
Other6
B-Symptoms
B-Symptoms(participants)Rituximab
Present14
Absent24

6 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • Erlangen, 91054, Germany
  • Grenzach-wyhlen, 79639, Germany
  • Göttingen, 37075, Germany
  • Hannover, 30625, Germany
  • Homburg/saar, 66424, Germany
  • Köln, 50924, Germany
  • Muenchen, 80336, Germany
  • Muenchen, 81377, Germany
  • Muenster, 48129, Germany
  • Stuttgart, 70376, Germany
  • Tübingen, 72076, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1997, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 6 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2013
First posted
Dec 2, 2013
Start
Jan 1997
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Nov 4, 2014
Last update
Dec 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01998893
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 2, 2013
Start date
Jan 1997
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Nov 4, 2014
Last update
Dec 3, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion